Share Price and Basic Stock Data
Last Updated: December 15, 2025, 4:00 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Brawn Biotech Ltd operates within the pharmaceuticals sector, an industry characterized by rapid innovation and regulatory scrutiny. The company’s stock is currently priced at ₹20.1, with a market capitalization of ₹6.03 Cr. Examining the revenue trajectory, Brawn’s sales reflected a volatile performance over the recent quarters. For instance, in March 2022, sales peaked at ₹2.89 Cr, but this fluctuated significantly, dropping to merely ₹0.12 Cr in June 2022. The subsequent quarters have shown a mix of recovery and decline, with the most recent quarter ending September 2023 reporting ₹2.92 Cr in sales. This inconsistency may raise eyebrows for potential investors, as sustained growth is often a critical factor for long-term investment decisions. Overall, while the company has recorded a trailing twelve-month revenue of ₹15.20 Cr, the erratic nature of its sales could signal underlying operational challenges that merit further scrutiny.
Profitability and Efficiency Metrics
Profitability metrics for Brawn Biotech paint a concerning picture. The company reported a negative operating profit margin (OPM) of -24.34% for March 2025, reflecting ongoing struggles with cost management and operational efficiency. Over the past several quarters, there has been a consistent pattern of losses, with net profits declining from ₹0.63 Cr in March 2022 to a stark loss of ₹1.63 Cr in March 2025. This trend raises questions about the company’s ability to convert sales into profits effectively. Additionally, the interest coverage ratio stands at a staggering -459.48, indicating that Brawn is significantly unable to meet its interest obligations. The cash conversion cycle, currently at 160.70 days, underscores inefficiencies in managing receivables and inventory. These profitability and efficiency metrics suggest that while Brawn has a presence in the market, it faces substantial hurdles that could hinder its financial recovery and long-term viability.
Balance Sheet Strength and Financial Ratios
The balance sheet of Brawn Biotech reveals a mixed picture of financial health. Notably, the company has zero borrowings, which is a strength, indicating that it is not over-leveraged and can potentially weather financial storms without the burden of debt. However, reserves have dwindled to ₹0.70 Cr as of March 2025, a stark decline from previous years, which raises concerns about its financial cushion. The return on equity (ROE) at 41.3% appears strong in isolation, but this figure must be viewed alongside its declining net profit margins and overall profitability challenges. The price-to-book value ratio stands at 1.45x, suggesting that the stock may be valued at a premium relative to its book value, which could deter value-focused investors. Collectively, while there are elements of balance sheet stability, the declining reserves and profitability metrics highlight the need for a robust turnaround strategy.
Shareholding Pattern and Investor Confidence
Brawn Biotech’s shareholding structure indicates a strong promoter presence, holding 53.66% of the company, which may instill confidence among investors regarding management’s commitment to the firm. However, the lack of foreign institutional investment (FIIs) is notable, particularly in an industry where international backing can provide stability and growth potential. Domestic institutional investors (DIIs) hold a mere 0.35%, reflecting limited institutional interest, while public shareholders account for 45.99%. The number of shareholders has decreased from over 6,200 to 3,958 in recent months, suggesting a potential decline in investor confidence or a shift in market sentiment. This fluctuation in shareholding could be a red flag for prospective investors, as it may indicate dissatisfaction with the company’s performance or outlook.
Outlook, Risks, and Final Insight
Looking ahead, Brawn Biotech faces a challenging landscape. The volatility in sales and persistent losses pose significant risks that could deter new investment. While the absence of debt is a positive aspect, the dwindling reserves and negative profitability metrics suggest that without a strategic overhaul, the company may struggle to regain investor confidence. Potential catalysts for improvement could include restructuring operations, enhancing efficiency, or exploring new market opportunities. However, the lack of institutional support and declining shareholder numbers indicate that the path to recovery may not be straightforward. Investors should weigh these risks carefully, considering both the potential for recovery and the ongoing operational challenges as they evaluate their positions in Brawn Biotech. Ultimately, while the company has strengths, it will need to address its weaknesses to foster a more favorable investment narrative.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 145 Cr. | 115 | 237/84.3 | 32.1 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.38 Cr. | 1.77 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,256 Cr. | 391 | 479/192 | 88.1 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.2 Cr. | 43.4 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 45.1 Cr. | 30.8 | 31.0/17.0 | 107 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,430.08 Cr | 1,157.00 | 52.78 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2.89 | 0.12 | 7.77 | 6.31 | 4.75 | 7.29 | 2.92 | 2.84 | 3.45 | 4.06 | 3.30 | 3.84 | 2.26 |
| Expenses | 2.61 | 0.09 | 8.11 | 6.32 | 4.88 | 7.45 | 3.31 | 3.42 | 3.84 | 4.56 | 3.62 | 4.24 | 2.81 |
| Operating Profit | 0.28 | 0.03 | -0.34 | -0.01 | -0.13 | -0.16 | -0.39 | -0.58 | -0.39 | -0.50 | -0.32 | -0.40 | -0.55 |
| OPM % | 9.69% | 25.00% | -4.38% | -0.16% | -2.74% | -2.19% | -13.36% | -20.42% | -11.30% | -12.32% | -9.70% | -10.42% | -24.34% |
| Other Income | -0.09 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.09 |
| Interest | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.02 | 0.00 | 0.02 | 0.03 | 0.04 | 0.02 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 |
| Profit before tax | 0.16 | 0.03 | -0.36 | -0.04 | -0.17 | -0.18 | -0.42 | -0.61 | -0.34 | -0.53 | -0.35 | -0.43 | -0.49 |
| Tax % | -293.75% | 0.00% | -2.78% | 0.00% | 258.82% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit | 0.63 | 0.02 | -0.35 | -0.04 | -0.61 | -0.17 | -0.42 | -0.61 | -0.34 | -0.53 | -0.34 | -0.43 | -0.49 |
| EPS in Rs | 2.10 | 0.07 | -1.17 | -0.13 | -2.03 | -0.57 | -1.40 | -2.03 | -1.13 | -1.77 | -1.13 | -1.43 | -1.63 |
Last Updated: May 31, 2025, 6:38 am
Below is a detailed analysis of the quarterly data for Brawn Biotech Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Sales, as of Mar 2025, the value is 2.26 Cr.. The value appears to be declining and may need further review. It has decreased from 3.84 Cr. (Dec 2024) to 2.26 Cr., marking a decrease of 1.58 Cr..
- For Expenses, as of Mar 2025, the value is 2.81 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 4.24 Cr. (Dec 2024) to 2.81 Cr., marking a decrease of 1.43 Cr..
- For Operating Profit, as of Mar 2025, the value is -0.55 Cr.. The value appears to be declining and may need further review. It has decreased from -0.40 Cr. (Dec 2024) to -0.55 Cr., marking a decrease of 0.15 Cr..
- For OPM %, as of Mar 2025, the value is -24.34%. The value appears to be declining and may need further review. It has decreased from -10.42% (Dec 2024) to -24.34%, marking a decrease of 13.92%.
- For Other Income, as of Mar 2025, the value is 0.09 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Dec 2024) to 0.09 Cr., marking an increase of 0.09 Cr..
- For Interest, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 0.00 Cr..
- For Depreciation, as of Mar 2025, the value is 0.03 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 0.03 Cr..
- For Profit before tax, as of Mar 2025, the value is -0.49 Cr.. The value appears to be declining and may need further review. It has decreased from -0.43 Cr. (Dec 2024) to -0.49 Cr., marking a decrease of 0.06 Cr..
- For Tax %, as of Mar 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 0.00%.
- For Net Profit, as of Mar 2025, the value is -0.49 Cr.. The value appears to be declining and may need further review. It has decreased from -0.43 Cr. (Dec 2024) to -0.49 Cr., marking a decrease of 0.06 Cr..
- For EPS in Rs, as of Mar 2025, the value is -1.63. The value appears to be declining and may need further review. It has decreased from -1.43 (Dec 2024) to -1.63, marking a decrease of 0.20.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:01 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 34.42 | 38.65 | 46.88 | 59.78 | 55.71 | 65.18 | 49.62 | 34.98 | 8.53 | 22.23 | 16.49 | 13.46 | 16.79 |
| Expenses | 33.97 | 38.09 | 45.44 | 58.53 | 53.75 | 64.01 | 48.89 | 35.58 | 10.53 | 22.53 | 17.95 | 15.23 | 17.55 |
| Operating Profit | 0.45 | 0.56 | 1.44 | 1.25 | 1.96 | 1.17 | 0.73 | -0.60 | -2.00 | -0.30 | -1.46 | -1.77 | -0.76 |
| OPM % | 1.31% | 1.45% | 3.07% | 2.09% | 3.52% | 1.80% | 1.47% | -1.72% | -23.45% | -1.35% | -8.85% | -13.15% | -4.53% |
| Other Income | -0.07 | 0.04 | 0.01 | 0.61 | 0.09 | 0.74 | 0.17 | 0.31 | 0.00 | 0.01 | 0.08 | 0.09 | 0.27 |
| Interest | 0.14 | 0.10 | 0.11 | 0.07 | 0.06 | 0.07 | 0.05 | 0.04 | 0.06 | 0.01 | 0.06 | 0.00 | 0.00 |
| Depreciation | 0.01 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.05 | 0.11 | 0.10 | 0.11 | 0.12 |
| Profit before tax | 0.23 | 0.47 | 1.31 | 1.76 | 1.96 | 1.81 | 0.82 | -0.36 | -2.11 | -0.41 | -1.54 | -1.79 | -0.61 |
| Tax % | 39.13% | 40.43% | 27.48% | 20.45% | 34.69% | 26.52% | 28.05% | 55.56% | -22.27% | 109.76% | -19.48% | -3.35% | |
| Net Profit | 0.14 | 0.28 | 0.95 | 1.39 | 1.28 | 1.33 | 0.59 | -0.55 | -1.64 | -0.87 | -1.25 | -1.74 | -0.61 |
| EPS in Rs | 0.47 | 0.93 | 3.17 | 4.63 | 4.27 | 4.43 | 1.97 | -1.83 | -5.47 | -2.90 | -4.17 | -5.80 | -2.03 |
| Dividend Payout % | 0.00% | 0.00% | 31.58% | 32.37% | 23.44% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 100.00% | 239.29% | 46.32% | -7.91% | 3.91% | -55.64% | -193.22% | -198.18% | 46.95% | -43.68% | -39.20% |
| Change in YoY Net Profit Growth (%) | 0.00% | 139.29% | -192.97% | -54.23% | 11.82% | -59.55% | -137.58% | -4.96% | 245.13% | -90.63% | 4.48% |
Brawn Biotech Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -10% |
| 5 Years: | -23% |
| 3 Years: | 16% |
| TTM: | 15% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -3% |
| TTM: | 46% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -4% |
| 5 Years: | -3% |
| 3 Years: | 5% |
| 1 Year: | 15% |
| Return on Equity | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | -18% |
| 3 Years: | -23% |
| Last Year: | -43% |
Last Updated: September 5, 2025, 2:46 pm
Balance Sheet
Last Updated: December 4, 2025, 2:34 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 |
| Reserves | 1.68 | 1.94 | 2.53 | 3.92 | 4.63 | 5.66 | 6.26 | 5.79 | 4.22 | 3.31 | 2.06 | 0.36 | 0.70 |
| Borrowings | 0.01 | 0.11 | 0.12 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 9.00 | 8.95 | 8.30 | 10.11 | 14.94 | 13.85 | 11.03 | 5.08 | 6.56 | 8.22 | 9.53 | 17.13 | 18.46 |
| Total Liabilities | 13.69 | 14.00 | 13.95 | 17.03 | 22.57 | 22.51 | 20.29 | 13.87 | 13.78 | 14.53 | 14.59 | 20.49 | 22.16 |
| Fixed Assets | 0.07 | 0.19 | 0.24 | 0.25 | 0.22 | 0.19 | 0.18 | 0.14 | 0.39 | 0.37 | 0.33 | 0.46 | 0.42 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.03 | 0.03 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 13.59 | 13.78 | 13.68 | 16.78 | 22.35 | 22.32 | 20.11 | 13.73 | 13.39 | 14.16 | 14.26 | 20.03 | 21.74 |
| Total Assets | 13.69 | 14.00 | 13.95 | 17.03 | 22.57 | 22.51 | 20.29 | 13.87 | 13.78 | 14.53 | 14.59 | 20.49 | 22.16 |
Below is a detailed analysis of the balance sheet data for Brawn Biotech Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 3.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 3.00 Cr..
- For Reserves, as of Sep 2025, the value is 0.70 Cr.. The value appears strong and on an upward trend. It has increased from 0.36 Cr. (Mar 2025) to 0.70 Cr., marking an increase of 0.34 Cr..
- For Borrowings, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 18.46 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 17.13 Cr. (Mar 2025) to 18.46 Cr., marking an increase of 1.33 Cr..
- For Total Liabilities, as of Sep 2025, the value is 22.16 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 20.49 Cr. (Mar 2025) to 22.16 Cr., marking an increase of 1.67 Cr..
- For Fixed Assets, as of Sep 2025, the value is 0.42 Cr.. The value appears to be declining and may need further review. It has decreased from 0.46 Cr. (Mar 2025) to 0.42 Cr., marking a decrease of 0.04 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 21.74 Cr.. The value appears strong and on an upward trend. It has increased from 20.03 Cr. (Mar 2025) to 21.74 Cr., marking an increase of 1.71 Cr..
- For Total Assets, as of Sep 2025, the value is 22.16 Cr.. The value appears strong and on an upward trend. It has increased from 20.49 Cr. (Mar 2025) to 22.16 Cr., marking an increase of 1.67 Cr..
Notably, the Reserves (0.70 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 0.44 | 0.45 | 1.32 | 1.25 | 1.96 | 1.17 | 0.73 | -0.60 | -2.00 | -0.30 | -1.46 | -1.77 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 88.65 | 87.07 | 71.63 | 79.50 | 98.60 | 92.17 | 110.34 | 96.83 | 120.24 | 87.35 | 85.88 | 92.47 |
| Inventory Days | 22.14 | 11.17 | 4.50 | 2.59 | 2.62 | 2.12 | 3.38 | 3.16 | 261.82 | 91.20 | 153.02 | 320.33 |
| Days Payable | 87.79 | 73.72 | 44.59 | 47.70 | 83.93 | 64.58 | 74.47 | 32.34 | 224.66 | 123.19 | 144.12 | 252.10 |
| Cash Conversion Cycle | 23.01 | 24.52 | 31.54 | 34.39 | 17.29 | 29.72 | 39.25 | 67.65 | 157.41 | 55.36 | 94.78 | 160.70 |
| Working Capital Days | 15.48 | 15.87 | 18.92 | 28.21 | 43.37 | 42.06 | 58.04 | 77.53 | 241.76 | 80.62 | 137.90 | 216.40 |
| ROCE % | 24.89% | 11.91% | 26.54% | 29.28% | 27.77% | 23.08% | 9.71% | -3.55% | -25.61% | -5.91% | -25.86% | -42.52% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -5.68 | -4.15 | -3.04 | -5.25 | -1.55 |
| Diluted EPS (Rs.) | -5.68 | -4.15 | -3.04 | -5.25 | -1.55 |
| Cash EPS (Rs.) | -5.42 | -3.83 | -2.53 | -5.30 | -1.72 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 11.21 | 16.88 | 21.03 | 24.07 | 29.31 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 11.21 | 16.88 | 21.03 | 24.07 | 29.31 |
| Revenue From Operations / Share (Rs.) | 44.88 | 54.98 | 74.09 | 28.73 | 116.57 |
| PBDIT / Share (Rs.) | -5.60 | -4.80 | -0.98 | -6.67 | -0.96 |
| PBIT / Share (Rs.) | -5.98 | -5.13 | -1.34 | -6.85 | -1.08 |
| PBT / Share (Rs.) | -5.99 | -5.15 | -1.37 | -7.06 | -1.20 |
| Net Profit / Share (Rs.) | -5.80 | -4.16 | -2.89 | -5.48 | -1.84 |
| PBDIT Margin (%) | -12.47 | -8.73 | -1.32 | -23.22 | -0.82 |
| PBIT Margin (%) | -13.32 | -9.33 | -1.81 | -23.84 | -0.92 |
| PBT Margin (%) | -13.35 | -9.36 | -1.85 | -24.56 | -1.02 |
| Net Profit Margin (%) | -12.92 | -7.56 | -3.90 | -19.07 | -1.57 |
| Return on Networth / Equity (%) | -51.75 | -24.61 | -13.75 | -22.77 | -6.26 |
| Return on Capital Employeed (%) | -16.07 | -19.06 | -6.21 | -27.53 | -3.60 |
| Return On Assets (%) | -8.49 | -8.54 | -5.97 | -11.92 | -3.96 |
| Asset Turnover Ratio (%) | 0.76 | 1.13 | 1.57 | 0.62 | 2.05 |
| Current Ratio (X) | 1.88 | 2.02 | 1.67 | 1.93 | 2.60 |
| Quick Ratio (X) | 0.75 | 1.09 | 1.07 | 1.18 | 2.54 |
| Inventory Turnover Ratio (X) | 1.63 | 0.00 | 0.00 | 0.00 | 5.09 |
| Interest Coverage Ratio (X) | -459.48 | -380.33 | -35.76 | -32.06 | -7.83 |
| Interest Coverage Ratio (Post Tax) (X) | -474.95 | -328.11 | -104.52 | -25.33 | -13.91 |
| Enterprise Value (Cr.) | 4.68 | 5.60 | 4.53 | 4.98 | 6.23 |
| EV / Net Operating Revenue (X) | 0.34 | 0.33 | 0.20 | 0.57 | 0.17 |
| EV / EBITDA (X) | -2.78 | -3.89 | -15.39 | -2.49 | -21.54 |
| MarketCap / Net Operating Revenue (X) | 0.36 | 0.36 | 0.22 | 0.60 | 0.18 |
| Price / BV (X) | 1.45 | 1.18 | 0.78 | 0.72 | 0.75 |
| Price / Net Operating Revenue (X) | 0.36 | 0.36 | 0.22 | 0.60 | 0.18 |
| EarningsYield | -0.35 | -0.20 | -0.17 | -0.31 | -0.08 |
After reviewing the key financial ratios for Brawn Biotech Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -5.68. This value is below the healthy minimum of 5. It has decreased from -4.15 (Mar 24) to -5.68, marking a decrease of 1.53.
- For Diluted EPS (Rs.), as of Mar 25, the value is -5.68. This value is below the healthy minimum of 5. It has decreased from -4.15 (Mar 24) to -5.68, marking a decrease of 1.53.
- For Cash EPS (Rs.), as of Mar 25, the value is -5.42. This value is below the healthy minimum of 3. It has decreased from -3.83 (Mar 24) to -5.42, marking a decrease of 1.59.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 11.21. It has decreased from 16.88 (Mar 24) to 11.21, marking a decrease of 5.67.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 11.21. It has decreased from 16.88 (Mar 24) to 11.21, marking a decrease of 5.67.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 44.88. It has decreased from 54.98 (Mar 24) to 44.88, marking a decrease of 10.10.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -5.60. This value is below the healthy minimum of 2. It has decreased from -4.80 (Mar 24) to -5.60, marking a decrease of 0.80.
- For PBIT / Share (Rs.), as of Mar 25, the value is -5.98. This value is below the healthy minimum of 0. It has decreased from -5.13 (Mar 24) to -5.98, marking a decrease of 0.85.
- For PBT / Share (Rs.), as of Mar 25, the value is -5.99. This value is below the healthy minimum of 0. It has decreased from -5.15 (Mar 24) to -5.99, marking a decrease of 0.84.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -5.80. This value is below the healthy minimum of 2. It has decreased from -4.16 (Mar 24) to -5.80, marking a decrease of 1.64.
- For PBDIT Margin (%), as of Mar 25, the value is -12.47. This value is below the healthy minimum of 10. It has decreased from -8.73 (Mar 24) to -12.47, marking a decrease of 3.74.
- For PBIT Margin (%), as of Mar 25, the value is -13.32. This value is below the healthy minimum of 10. It has decreased from -9.33 (Mar 24) to -13.32, marking a decrease of 3.99.
- For PBT Margin (%), as of Mar 25, the value is -13.35. This value is below the healthy minimum of 10. It has decreased from -9.36 (Mar 24) to -13.35, marking a decrease of 3.99.
- For Net Profit Margin (%), as of Mar 25, the value is -12.92. This value is below the healthy minimum of 5. It has decreased from -7.56 (Mar 24) to -12.92, marking a decrease of 5.36.
- For Return on Networth / Equity (%), as of Mar 25, the value is -51.75. This value is below the healthy minimum of 15. It has decreased from -24.61 (Mar 24) to -51.75, marking a decrease of 27.14.
- For Return on Capital Employeed (%), as of Mar 25, the value is -16.07. This value is below the healthy minimum of 10. It has increased from -19.06 (Mar 24) to -16.07, marking an increase of 2.99.
- For Return On Assets (%), as of Mar 25, the value is -8.49. This value is below the healthy minimum of 5. It has increased from -8.54 (Mar 24) to -8.49, marking an increase of 0.05.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.76. It has decreased from 1.13 (Mar 24) to 0.76, marking a decrease of 0.37.
- For Current Ratio (X), as of Mar 25, the value is 1.88. This value is within the healthy range. It has decreased from 2.02 (Mar 24) to 1.88, marking a decrease of 0.14.
- For Quick Ratio (X), as of Mar 25, the value is 0.75. This value is below the healthy minimum of 1. It has decreased from 1.09 (Mar 24) to 0.75, marking a decrease of 0.34.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.63. This value is below the healthy minimum of 4. It has increased from 0.00 (Mar 24) to 1.63, marking an increase of 1.63.
- For Interest Coverage Ratio (X), as of Mar 25, the value is -459.48. This value is below the healthy minimum of 3. It has decreased from -380.33 (Mar 24) to -459.48, marking a decrease of 79.15.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -474.95. This value is below the healthy minimum of 3. It has decreased from -328.11 (Mar 24) to -474.95, marking a decrease of 146.84.
- For Enterprise Value (Cr.), as of Mar 25, the value is 4.68. It has decreased from 5.60 (Mar 24) to 4.68, marking a decrease of 0.92.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.34. This value is below the healthy minimum of 1. It has increased from 0.33 (Mar 24) to 0.34, marking an increase of 0.01.
- For EV / EBITDA (X), as of Mar 25, the value is -2.78. This value is below the healthy minimum of 5. It has increased from -3.89 (Mar 24) to -2.78, marking an increase of 1.11.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.36. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.36.
- For Price / BV (X), as of Mar 25, the value is 1.45. This value is within the healthy range. It has increased from 1.18 (Mar 24) to 1.45, marking an increase of 0.27.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.36. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.36.
- For EarningsYield, as of Mar 25, the value is -0.35. This value is below the healthy minimum of 5. It has decreased from -0.20 (Mar 24) to -0.35, marking a decrease of 0.15.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Brawn Biotech Ltd:
- Net Profit Margin: -12.92%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -16.07% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -51.75% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -474.95
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.75
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 52.78)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -12.92%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | C-64, First Floor, New Delhi Delhi 110024 | solution@brawnbiotech.com http://www.brawnbiotech.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Brij Raj Gupta | Director |
| Mrs. Brij Bala Gupta | Director |
| Mr. Mayank Jain | Independent Director |
| Mrs. Pooja Jha | Independent Director |
FAQ
What is the intrinsic value of Brawn Biotech Ltd?
Brawn Biotech Ltd's intrinsic value (as of 15 December 2025) is 62.18 which is 203.32% higher the current market price of 20.50, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 6.15 Cr. market cap, FY2025-2026 high/low of 26.0/15.5, reserves of ₹0.70 Cr, and liabilities of 22.16 Cr.
What is the Market Cap of Brawn Biotech Ltd?
The Market Cap of Brawn Biotech Ltd is 6.15 Cr..
What is the current Stock Price of Brawn Biotech Ltd as on 15 December 2025?
The current stock price of Brawn Biotech Ltd as on 15 December 2025 is 20.5.
What is the High / Low of Brawn Biotech Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Brawn Biotech Ltd stocks is 26.0/15.5.
What is the Stock P/E of Brawn Biotech Ltd?
The Stock P/E of Brawn Biotech Ltd is .
What is the Book Value of Brawn Biotech Ltd?
The Book Value of Brawn Biotech Ltd is 12.3.
What is the Dividend Yield of Brawn Biotech Ltd?
The Dividend Yield of Brawn Biotech Ltd is 0.00 %.
What is the ROCE of Brawn Biotech Ltd?
The ROCE of Brawn Biotech Ltd is 42.5 %.
What is the ROE of Brawn Biotech Ltd?
The ROE of Brawn Biotech Ltd is 41.3 %.
What is the Face Value of Brawn Biotech Ltd?
The Face Value of Brawn Biotech Ltd is 10.0.